<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| AML-11 | Internal request: Review the category designation for hypomethylating agents (5-azacytidine, decitabine) across all performance statuses for patients aged ≥ 60 years. Based upon the data in the noted references, the panel consensus was to change the category designation for hypomethylating agents (5-azacytidine, decitabine) from a category 2B to a category 2A for patients with a performance status 0-2. | • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.  
NO 2  
ABSTAIN 1 |
| AML-12 | Internal request: Review the category designation for hypomethylating agents (5-azacytidine, decitabine) across all performance statuses for patients aged ≥ 60 years. Based upon the data in the noted references, the panel consensus was to change the category designation for hypomethylating agents (5-azacytidine, decitabine) from a category 2B to a category 2A for patients with a performance status > 2. | • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.  
NO 2  
ABSTAIN 1 |
| AMF-F | Internal request: Suggest adding clofarabine + cytarabine + GCSF as a salvage chemotherapy regimen option. Based upon the data in the noted reference, the panel consensus was to add clofarabine + cytarabine + GCSF as a salvage chemotherapy regimen option. | • Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155:182-189 | YES 15  
NO 2  
ABSTAIN 2 |
**Guideline Page and Request**

AML-12 and AMF-F  
Internal request:  
Suggest adding low intensity therapy (low dose cytarabine or hypomethylating agents [5-azacytidine, decitabine]) as induction therapy for patients with significant comorbidities and as salvage chemotherapy regimen options for patients not able to tolerate aggressive regimens.

**Panel Discussion**

Based upon the data in the noted references, the panel consensus was to add low dose cytarabine or hypomethylating agents (5-azacytidine, decitabine) as induction therapy for patients with significant comorbidities and as salvage chemotherapy regimen options for patients not able to tolerate aggressive regimens.

**References**


**Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>